argenx SE (ARGX)

About argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Latest reported results

argenx SE reported revenue of $1.72 billion for Q4 FY2026, down 46.3% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 499 institutions reported holding ARGX, with 28.2 million shares worth $26.0 billion in aggregate. The largest reported holders were FMR, T. Rowe Price and Janus Henderson (Jupiter Topco). Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.

More on ARGX

• ARGX sentiment: whether news and social coverage of argenx SE leans bullish or bearish, and the stories driving it.
• ARGX ownership: all 499 reporting institutions, plus insider and congressional trades.
• ARGX financials: revenue, net income, operating margin and free cash flow through Q4 FY2026.

SentiSense also tracks daily options readings for argenx SE: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions